CTLA4 and melanoma: Immune checkpoint inhibitors (ICI) targeting program cell death protein (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have demonstrated remarkable efficacy in treating advanced melanoma, leading to durable responses and improved survival rates.5–7 However, not all patients respond equally to these treatments, and some may experience immune-related adverse events (irAEs) due to inappropriate immune system activation.